Home

Download

Statistics

Examples

Help

Contact

Fusion Protein:RASAL2-GALNTL6

Fusion Gene and Fusion Protein Summary

Fusion gene summary

Fusion partner gene information	Fusion gene name: RASAL2-GALNTL6
	FusionPDB ID: 72421
	FusionGDB2.0 ID: 72421
		Hgene	Tgene
	Gene symbol	RASAL2	GALNTL6
	Gene ID	9462	442117
	Gene name	RAS protein activator like 2	polypeptide N-acetylgalactosaminyltransferase like 6
	Synonyms	NGAP	GALNACT20\|GALNT17\|GalNAc-T6L
	Cytomap	1q25.2	4q34.1
	Type of gene	protein-coding	protein-coding
	Description	ras GTPase-activating protein nGAPRASAL2/ACVR1 fusionRas protein activator like 1	polypeptide N-acetylgalactosaminyltransferase-like 6GaNTase 17GalNAc transferase 17UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 17UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 20UDP-N-acetyl-alpha-D-gala
	Modification date	20200313	20200313
	UniProtAcc	.	Q49A17 Main function of 5'-partner protein: FUNCTION: Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. {ECO:0000250}.
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000367649, ENST00000448150, ENST00000462775, ENST00000465723,	ENST00000457021, ENST00000511251, ENST00000506823, ENST00000508122,
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)	* DoF score	19 X 13 X 10=2470	16 X 15 X 8=1920
	# samples	20	18
	** MAII score	log2(20/2470*10)=-3.62643913669732 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0	log2(18/1920*10)=-3.41503749927884 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0
Fusion gene context	PubMed: RASAL2 [Title/Abstract] AND GALNTL6 [Title/Abstract] AND fusion [Title/Abstract]
Fusion neoantigen context	PubMed: RASAL2 [Title/Abstract] AND GALNTL6 [Title/Abstract] AND neoantigen [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	RASAL2(178269253)-GALNTL6(173730512), # samples:3
Anticipated loss of major functional domain due to fusion event.	RASAL2-GALNTL6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. RASAL2-GALNTL6 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF. RASAL2-GALNTL6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF. RASAL2-GALNTL6 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.

* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Tgene	GALNTL6	GO:0018243	protein O-linked glycosylation via threonine	22186971

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr1:178269253/chr4:173730512)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Retention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

Fusion gene breakpoints across RASAL2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Fusion gene breakpoints across GALNTL6 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Fusion Amino Acid Sequences

Fusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.

Henst

Tenst

Hgene

Hchr

Hbp

Hstrand

Tgene

Tchr

Tbp

Tstrand

Seq length
(transcript)

BP loci
(transcript)

Predicted start
(transcript)

Predicted stop
(transcript)

Seq length
(amino acids)

ENST00000448150

RASAL2

chr1

178269253

ENST00000506823

GALNTL6

chr4

173730512

3933

1221

410

2473

687

ENST00000448150

RASAL2

chr1

178269253

ENST00000508122

GALNTL6

chr4

173730512

2474

1221

410

2473

688

ENST00000367649

RASAL2

chr1

178269253

ENST00000506823

GALNTL6

chr4

173730512

3521

809

166

2061

631

ENST00000367649

RASAL2

chr1

178269253

ENST00000508122

GALNTL6

chr4

173730512

2062

809

166

2061

632

DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.

Henst	Tenst	Hgene	Hchr	Hbp	Hstrand	Tgene	Tchr	Tbp	Tstrand	No-coding score	Coding score
ENST00000448150	ENST00000506823	RASAL2	chr1	178269253	+	GALNTL6	chr4	173730512	+	0.00218393	0.9978161
ENST00000448150	ENST00000508122	RASAL2	chr1	178269253	+	GALNTL6	chr4	173730512	+	0.010844637	0.98915535
ENST00000367649	ENST00000506823	RASAL2	chr1	178269253	+	GALNTL6	chr4	173730512	+	0.00121074	0.99878925
ENST00000367649	ENST00000508122	RASAL2	chr1	178269253	+	GALNTL6	chr4	173730512	+	0.005204386	0.9947956

Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for RASAL2-GALNTL6

+/-13 AA sequence from the breakpoints of the fusion protein sequences.

Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Length(fusion protein)	BP in fusion protein	Peptide
RASAL2	chr1	178269253	GALNTL6	chr4	173730512	1221	269	GQFPEYPPEGATKLEHLKDKLEEYMA
RASAL2	chr1	178269253	GALNTL6	chr4	173730512	809	213	GQFPEYPPEGATKLEHLKDKLEEYMA

Top

Potential FusionNeoAntigen Information of RASAL2-GALNTL6 in HLA I

Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

RASAL2-GALNTL6_178269253_173730512.msa

Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)

Fusion gene	Hchr	Hbp	Tgene	Tchr	Tbp	HLA I	FusionNeoAntigen peptide	Binding score	Immunogenic score	Neoantigen start (at BP 13)	Neoantigen end (at BP 13)
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:01	YPPEGATKL	0.9845	0.9691	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:03	YPPEGATKL	0.9825	0.9638	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:08	YPPEGATKL	0.9437	0.9071	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:05	YPPEGATKL	0.9196	0.7896	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:04	YPPEGATKL	0.9084	0.9725	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:02	YPPEGATKL	0.9084	0.9725	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B15:10	YPPEGATKL	0.8003	0.7073	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B15:37	YPPEGATKL	0.5926	0.7799	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B39:01	YPPEGATKL	0.5584	0.9669	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B14:01	YPPEGATKL	0.5503	0.8573	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B14:02	YPPEGATKL	0.5503	0.8573	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B08:01	YPPEGATKL	0.048	0.8419	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B08:09	YPPEGATKL	0.0469	0.6842	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:12	YPPEGATKL	0.9084	0.9725	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C03:08	YPPEGATKL	0.8545	0.9255	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B14:03	YPPEGATKL	0.7405	0.8506	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B51:07	YPPEGATKL	0.6702	0.8048	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B39:09	YPPEGATKL	0.6378	0.7685	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B39:10	YPPEGATKL	0.5945	0.9693	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C08:03	YPPEGATKL	0.5353	0.9867	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C08:13	YPPEGATKL	0.4684	0.9724	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C08:04	YPPEGATKL	0.4684	0.9724	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C04:06	YPPEGATKL	0.3622	0.9615	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C07:13	YPPEGATKL	0.3161	0.9648	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C04:14	YPPEGATKL	0.2599	0.7769	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C01:30	YPPEGATKL	0.2422	0.9678	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C07:29	YPPEGATKL	0.2379	0.9768	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C01:17	YPPEGATKL	0.1395	0.9563	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B42:02	YPPEGATKL	0.1279	0.8472	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B42:01	YPPEGATKL	0.1047	0.8386	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C08:15	YPPEGATKL	0.0375	0.9589	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C05:09	YPPEGATKL	0.0332	0.9464	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C04:10	YPPEGATKL	0.0251	0.7961	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C04:07	YPPEGATKL	0.0226	0.8182	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:23	YPPEGATKL	0.9852	0.961	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B07:13	YPPEGATKL	0.9851	0.834	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:77	YPPEGATKL	0.9845	0.9691	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:13	YPPEGATKL	0.9814	0.9643	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C03:05	YPPEGATKL	0.9652	0.9368	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C03:04	YPPEGATKL	0.9583	0.99	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C03:03	YPPEGATKL	0.9583	0.99	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C03:17	YPPEGATKL	0.948	0.9786	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:17	YPPEGATKL	0.9245	0.9158	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:30	YPPEGATKL	0.9245	0.9158	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:09	YPPEGATKL	0.9084	0.9725	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C03:67	YPPEGATKL	0.8793	0.9844	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:24	YPPEGATKL	0.8547	0.9765	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:11	YPPEGATKL	0.803	0.9545	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B78:02	YPPEGATKL	0.657	0.5555	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C03:06	YPPEGATKL	0.6543	0.9914	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B67:01	YPPEGATKL	0.6293	0.8795	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B39:11	YPPEGATKL	0.5484	0.8898	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C08:01	YPPEGATKL	0.5353	0.9867	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B15:09	YPPEGATKL	0.5036	0.6622	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C04:04	YPPEGATKL	0.288	0.9343	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C07:04	YPPEGATKL	0.2429	0.912	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C01:02	YPPEGATKL	0.1639	0.9562	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B08:12	YPPEGATKL	0.1021	0.8902	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C01:03	YPPEGATKL	0.087	0.9214	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B08:18	YPPEGATKL	0.048	0.8419	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B18:07	YPPEGATKL	0.0467	0.9713	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C08:02	YPPEGATKL	0.0375	0.9589	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C05:01	YPPEGATKL	0.0332	0.9464	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C04:03	YPPEGATKL	0.0274	0.8714	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C04:01	YPPEGATKL	0.0226	0.8182	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-C18:01	YPPEGATKL	0.0221	0.8215	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B35:43	YPPEGATKL	0.0112	0.8947	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B15:08	YPPEGATKL	0.0105	0.8928	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-B15:11	YPPEGATKL	0.0095	0.8743	5	14
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	809	HLA-A30:01	ATKLEHLKDK	0.974	0.8515	10	20

Top

Potential FusionNeoAntigen Information of RASAL2-GALNTL6 in HLA II

Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).

Fusion gene

Hchr

Hbp

Tgene

Tchr

Tbp

HLA II

FusionNeoAntigen peptide

Neoantigen start (at BP 13)

Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of RASAL2-GALNTL6

3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.

File name	BPseq	Hgene	Tgene	Hchr	Hbp	Tchr	Tbp	AAlen
6851	PPEGATKLEHLKDK	RASAL2	GALNTL6	chr1	178269253	chr4	173730512	809

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of RASAL2-GALNTL6

Virtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.

HLA allele	PDB ID	File name	BPseq	Docking score	Glide score
HLA-B14:02	3BVN	6851	PPEGATKLEHLKDK	-4.94269	-5.69719
HLA-B14:02	3BVN	6851	PPEGATKLEHLKDK	-4.51593	-4.71043
HLA-B52:01	3W39	6851	PPEGATKLEHLKDK	-8.249	-8.4435
HLA-B52:01	3W39	6851	PPEGATKLEHLKDK	-7.17937	-7.93387
HLA-A11:01	4UQ2	6851	PPEGATKLEHLKDK	-8.03173	-8.22623
HLA-A11:01	4UQ2	6851	PPEGATKLEHLKDK	-4.95743	-5.71193
HLA-A24:02	5HGA	6851	PPEGATKLEHLKDK	-6.4174	-6.6119
HLA-A24:02	5HGA	6851	PPEGATKLEHLKDK	-4.65241	-5.40691
HLA-B27:05	6PYJ	6851	PPEGATKLEHLKDK	-7.17858	-7.93308
HLA-B27:05	6PYJ	6851	PPEGATKLEHLKDK	-3.10309	-3.29759
HLA-B44:05	3DX8	6851	PPEGATKLEHLKDK	-4.08639	-4.28089
HLA-B44:05	3DX8	6851	PPEGATKLEHLKDK	-3.78094	-4.53544

Top

Vaccine Design for the FusionNeoAntigens of RASAL2-GALNTL6

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.

Fusion gene	Hchr	Hbp	Tchr	Tbp	Start in +/-13AA	End in +/-13AA	FusionNeoAntigen peptide sequence	FusionNeoAntigen RNA sequence
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	10	20	ATKLEHLKDK	CTAAACTGGAACACCTGAAGGATAAATTGG
RASAL2-GALNTL6	chr1	178269253	chr4	173730512	5	14	YPPEGATKL	CACCAGAGGGCGCCACTAAACTGGAAC

mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.

Fusion gene

Hchr

Hbp

Tchr

Tbp

Start in +/-13AA

End in +/-13AA

FusionNeoAntigen peptide

FusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of RASAL2-GALNTL6

These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.

Cancer type	Fusion gene	Hchr	Hbp	Henst	Tchr	Tbp	Tenst	Sample
LUAD	RASAL2-GALNTL6	chr1	178269253	ENST00000367649	chr4	173730512	ENST00000506823	TCGA-78-8640-01A

Top

Potential target of CAR-T therapy development for RASAL2-GALNTL6

Predicted 3D structure. We used RoseTTAFold.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features

* Minus value of BPloci means that the break point is located before the CDS.

- In-frame and retained 'Transmembrane'.

Partner

Gene

Hbp

Tbp

ENST

Strand

BPexon

TotalExon

Protein feature loci

*BPloci

TotalLen

Protein feature

Protein feature note

Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.

Hgene

Hchr

Hbp

Henst

Tgene

Tchr

Tbp

Tenst

DeepLoc result

Top

Related Drugs to RASAL2-GALNTL6

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Top

Related Diseases to RASAL2-GALNTL6

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

	Fusion Gene and Fusion Protein Summary
	Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)
	Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)
	Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)
	Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)
	Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)
	Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)
	Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)
	Potential target of CAR-T therapy development
	Information on the samples that have these potential fusion neoantigens
	Fusion Protein Targeting Drugs - (Manual Curation)
	Fusion Protein Related diseases - (Manual Curation)